RLYB — Rallybio Corporation
Is RLYB overbought or oversold? Here is the current MarketMoodz read.
Rallybio Corporation (RLYB) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $15.43. The rating moved from Oversold to Neutral on November 14, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$15.43
- Last changeMoved from Oversold to Neutral on November 14, 2026
- SectorHealthcare
- IndustryBiotechnology
AI analysis
Rallybio is a clinical-stage biopharma with value driven primarily by pipeline milestones and financing cadence. The company lacks material product revenue, so near-term share performance will hinge on clinical readouts, cash runway clarity and any partnership or M&A activity. Current market caution and defensive sector flows favor larger-cap, diversified pharma, which may limit appetite for smaller, riskier biotechs in the near term; monitoring upcoming catalysts and liquidity metrics is essential for assessing directional moves.
Key factors
- Clinical-stage pipeline with binary near-term clinical and regulatory milestones that drive outsized share moves
- Limited or no material product revenue; profile dependent on cash runway and financing activity
- Potential acquirer interest amid larger-cap pharma consolidation and active licensing dynamics in specialty/rare disease franchises
- Sectorwide defensive flows favor large-cap pharma over small biotech in the current risk-off environment, weighing near-term investor appetite
- Specialty distributor and infusion channel trends could support downstream access for injectable/complex therapies over time
Risks
- Clinical trial failure or delayed readouts that would materially reduce valuation
- Cash burn and the need for dilutionary financing if cash runway is short or milestones slip
- Regulatory risk including stricter payer coverage or Medicare policy changes that could affect reimbursement economics
- Competition from larger biotech/pharma with deeper commercial and R&D resources
- Low liquidity and volatility that can amplify downside in risk-off market conditions
See today's live rating, score and targets
Members see the live hourly rating for RLYB — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.